PL2599774T3 - Skondensowane związki pirydynowe, jako ligandy receptorów kannabinoidowych cb2 - Google Patents

Skondensowane związki pirydynowe, jako ligandy receptorów kannabinoidowych cb2

Info

Publication number
PL2599774T3
PL2599774T3 PL11812552T PL11812552T PL2599774T3 PL 2599774 T3 PL2599774 T3 PL 2599774T3 PL 11812552 T PL11812552 T PL 11812552T PL 11812552 T PL11812552 T PL 11812552T PL 2599774 T3 PL2599774 T3 PL 2599774T3
Authority
PL
Poland
Prior art keywords
receptor ligands
cannabinoid receptor
pyridine compounds
condensed pyridine
condensed
Prior art date
Application number
PL11812552T
Other languages
English (en)
Inventor
Yuji Matsushima
Minoru Kameda
Shugo Honda
Yukihito Sugano
Hiroyuki Usuda
Tadashi Terasaka
Takeshi Terasawa
Fusako Nishigaki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL2599774T3 publication Critical patent/PL2599774T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/34Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL11812552T 2010-07-29 2011-07-28 Skondensowane związki pirydynowe, jako ligandy receptorów kannabinoidowych cb2 PL2599774T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010170338 2010-07-29

Publications (1)

Publication Number Publication Date
PL2599774T3 true PL2599774T3 (pl) 2017-01-31

Family

ID=45530163

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11812552T PL2599774T3 (pl) 2010-07-29 2011-07-28 Skondensowane związki pirydynowe, jako ligandy receptorów kannabinoidowych cb2

Country Status (25)

Country Link
US (1) US8791106B2 (pl)
EP (1) EP2599774B1 (pl)
JP (1) JP5776691B2 (pl)
KR (1) KR101760158B1 (pl)
CN (1) CN103038218B (pl)
AU (1) AU2011283563C1 (pl)
BR (1) BR112013003481A8 (pl)
CA (1) CA2806821C (pl)
CY (1) CY1118049T1 (pl)
DK (1) DK2599774T3 (pl)
EA (1) EA024353B1 (pl)
ES (1) ES2592161T3 (pl)
HR (1) HRP20161111T1 (pl)
HU (1) HUE031639T2 (pl)
IL (1) IL224342A (pl)
LT (1) LT2599774T (pl)
MX (1) MX341394B (pl)
PL (1) PL2599774T3 (pl)
PT (1) PT2599774T (pl)
RS (1) RS55186B1 (pl)
SI (1) SI2599774T1 (pl)
TW (1) TWI482622B (pl)
UA (1) UA109550C2 (pl)
WO (1) WO2012014963A1 (pl)
ZA (1) ZA201300572B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI610916B (zh) * 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
SI3043784T1 (sl) 2013-09-09 2019-08-30 Peloton Therapeutics, Inc. Aril etri in njihova uporaba
EP3267792A4 (en) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
BR112019008821A8 (pt) * 2016-11-01 2020-02-04 Hoffmann La Roche derivados de piridazina como moduladores de rorc

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
EP1471049A4 (en) * 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
EP1736470A3 (en) * 2002-08-21 2007-04-04 Glaxo Group Limited Pyrimidine derivatives as CB2 cannabinoid receptor modulators
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0412908D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Compounds
JP2008501758A (ja) * 2004-06-09 2008-01-24 グラクソ グループ リミテッド ピロロピリジン誘導体
GB0516380D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
GB0516379D0 (en) 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
EA200800562A1 (ru) * 2005-08-09 2008-06-30 Глаксо Груп Лимитед Производные имидазопиридина в качестве лигандов каннабиноидного рецептора
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
CN101296699B (zh) * 2005-10-21 2013-01-02 田边三菱制药株式会社 吡唑并[1,5-a]嘧啶化合物
WO2008014199A2 (en) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
AU2007315848A1 (en) * 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2226323A1 (en) * 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives

Also Published As

Publication number Publication date
LT2599774T (lt) 2016-10-10
EA024353B1 (ru) 2016-09-30
US20130143874A1 (en) 2013-06-06
CN103038218A (zh) 2013-04-10
CA2806821A1 (en) 2012-02-02
BR112013003481A8 (pt) 2017-12-26
AU2011283563A1 (en) 2013-02-21
JPWO2012014963A1 (ja) 2013-09-12
EP2599774A4 (en) 2014-01-08
DK2599774T3 (en) 2016-10-24
CY1118049T1 (el) 2017-05-17
BR112013003481A2 (pt) 2016-06-21
EP2599774B1 (en) 2016-07-06
IL224342A (en) 2017-11-30
CA2806821C (en) 2017-05-09
HUE031639T2 (en) 2017-07-28
AU2011283563C1 (en) 2015-01-22
WO2012014963A1 (ja) 2012-02-02
JP5776691B2 (ja) 2015-09-09
PT2599774T (pt) 2016-09-23
KR20130136442A (ko) 2013-12-12
HRP20161111T1 (hr) 2016-11-18
MX2013001202A (es) 2013-06-28
RS55186B1 (sr) 2017-01-31
EA201390180A1 (ru) 2013-07-30
US8791106B2 (en) 2014-07-29
AU2011283563B2 (en) 2014-07-10
TWI482622B (zh) 2015-05-01
ES2592161T3 (es) 2016-11-28
CN103038218B (zh) 2016-04-13
SI2599774T1 (sl) 2017-03-31
KR101760158B1 (ko) 2017-07-20
TW201208687A (en) 2012-03-01
MX341394B (es) 2016-08-18
UA109550C2 (uk) 2015-09-10
ZA201300572B (en) 2014-03-26
EP2599774A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
PL2599774T3 (pl) Skondensowane związki pirydynowe, jako ligandy receptorów kannabinoidowych cb2
ZA201101590B (en) Substituted benzamides as cannabinoid receptor ligands
PL2621903T3 (pl) Związki n-heteroarylu
EP2219629A4 (en) NEW COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
EP2606021A4 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
ZA201306328B (en) Novel compounds as histamine h3 receptor ligands
AP3307A (en) Heteroaryl compounds as 5-HT4 receptor ligands
ZA201400708B (en) Novel estrogen receptor ligands
SG10201503202QA (en) Phase separated composite
HK1180955A1 (en) Heterocyclyl compounds as histamine h3 receptor ligands h3
GB201105979D0 (en) Novel estrogen receptor ligands
HK1183877A1 (en) Substituted pyridine compound
EP2872138A4 (en) NEUROPROTECTIVE AGONISTS OF CB2 RECEPTORS
EP2709648A4 (en) COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR
EP2502393A4 (en) PHASE COMPENSATOR
GB201013921D0 (en) Novel estrogen receptor ligands
GB201011859D0 (en) Novel estrogen receptor ligands
GB201004377D0 (en) Novel estrogen receptor ligands
GB201105984D0 (en) Novel estrogen receptor ligands
GB201105983D0 (en) Novel estrogen receptor ligands
TWM402058U (en) Multifunctional clothes hanger